Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Odds ratios and 95% confidence intervals for the risk of osteoporotic fracture associated with PPI use compared to exclusive H2RA useOsteoporotic fractureOR (95% CI)CasesControlsn(%)n(%)CrudeAdjustedaAny use H2RA use35,929(61)192,458(65)1 (Reference)1 (Reference) PPI use23,311(39)103,742(35)1.24 (1.22 to 1.27)1.11 (1.08 to 1.13)Duration of use H2RA use35,929(61)192,458(65)1 (Reference)1 (Reference) < 30 days10,715(17)51,337(18)1.15 (1.13 to 1.18)1.08 (1.06 to 1.11) 30 to 59 days4773(7)21,788(8)1.22 (1.18 to 1.26)1.09 (1.05 to 1.13) 60 to 89 days2405(4)10,408(4)1.29 (1.23 to 1.35)1.11 (1.06 to 1.17) 90 to 179 days2747(4)11,249(5)1.37 (1.31 to 1.44)1.13 (1.08 to 1.19) 180 to 364 days1505(2)5417(3)1.57 (1.48 to 1.67)1.18 (1.11 to 1.26) ≥ 365 days1166(1)3543(2)1.88 (1.75 to 2.01)1.42 (1.32 to 1.52) P for trend< 0.001< 0.001Recent useb No recent use53,019(90)274,084(93)1 (Reference)1 (Reference) One quarter3812(6)14,123(5)1.41 (1.35 to 1.46)1.24 (1.19 to 1.29) Two quarters1156(2)4119(1)1.47 (1.37 to 1.57)1.19 (1.11 to 1.27) Three quarters564(1)1793(1)1.64 (1.49 to 1.81)1.32 (1.20 to 1.46) All quarters (regular use)689(1)2081(1)1.73 (1.59 to 1.89)1.37 (1.26 to 1.50) P for trend< 0.001< 0.001PPI use was defined as having been prescribed PPI at least once during the follow-up periodConcomitant diseases were defined using the ICD-10 codes and included chronic obstructive pulmonary disease (J44, 45), testicular dysfunction (E29.1), hypothalamic dysfunction (E23.0), hyperthyroidism (E05), hyperparathyroidism (E21), Cushing’s syndrome (E24), hyperprolactinemia (E22.1), vitamin D deficiency (E55.9), idiopathic hypercalciuria (E83.5), diabetes (E11: 14 and diabetic agents), anorexia nervosa (F50.0, 50.1), systemic lupus erythematous (M32), hypertension (I10: 13, I15, and use of antihypertensive agents), intestinal absorption disorder (K90), inflammatory bowel disease (K50, 51), chronic kidney disease (N18), and secondary amenorrhea (N91.1)Abbreviations: H2RA histamine-2 receptor antagonist, PPI proton pump inhibitor, Ref. referenceaAdjusted for age, sex, body mass index, alcohol drinking, smoking, physical activity, bisphosphonates, glucocorticoids, anticonvulsants, hormone replacement therapy, warfarin, heparin, antacids, selective serotonin reuptake inhibitors, benzodiazepines, tricyclic antidepressants, diabetes mellitus, chronic obstructive pulmonary disease, hypothyroidism, hypopituitarism, hyperparathyroidism, Cushing’s syndrome, hyperprolactinemia, vitamin D deficiency, idiopathic hypercalcemia, intestinal absorption disorder, chronic liver disease, rheumatoid arthritis, hyperthyroidism, chronic kidney disease, chronic obstructive pulmonary disease, anorexia nervosa, systemic lupus erythematosus, inflammatory bowel disease, secondary amenorrhea, and hypertensive diseasebThe number of quarters with PPI use during the year prior to fracture was identified.

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Case-control study.

Case-control study

Compares people with an outcome against people without it, examining exposures.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease

Source: Article title.

A total of 35,520,188 patients were taking either PPI or H2RA for PUD and GERD from January 1, 2006 to December 31, 2015.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease

Case-control study · BMC Geriatrics · 2020

Original publication title

Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease

Joo-Hyun Park; Jessie Lee; Su-Yeon Yu; Jin-Hyung Jung; Kyungdo Han; Do-Hoon Kim; Jinnie Rhee

© The Author(s) 2020

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

The risk of osteoporotic fracture increased with the duration of PPI use, especially when PPI was used for ≥1 year and regularly in the recent 1 year.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Patients with peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) are more likely to receive long-term therapy with proton pump inhibitors (PPIs). This study aimed to investigate the risk of osteoporotic fractures in PPI users compared to histamine-2 receptor antagonist (H2RA) users and the association between fractures and the duration and regular use of PPI.

Source: Background

Abstract: What methods does the paper describe?

A population-based, nationwide nested case-control study from January 2006 to December 2015 was performed using Korean National Health Insurance Service claims data. We included patients ≥50 years of age, without previous fractures, newly prescribed with PPI or H2RA, and diagnosed with PUD or GERD from 2006 to 2015. Patients with osteoporotic fracture (n = 59,240) were matched with the non-fracture control group (n = 296,200) at a 1:5 ratio based on sex, age, cohort entry date, follow-up duration, and bisphosphonate use.

The osteoporotic fractures were defined using the diagnostic codes of claims data (M80, M81, M82, M484, M485, S220, S221, S320, S327, S422, S423, S525, S526, S72).

Source: Methods

Abstract: Results

The higher the cumulative use of PPIs, the higher the osteoporotic fracture risk (P for trend < 0.001). The risk of osteoporotic fracture in the patients whose cumulative use of PPI was more than 1 year was higher than that of others (OR: 1.42, 95% CI: 1.32 to 1.52). Patients who regularly used PPI in the recent 1 year had a higher risk of osteoporotic fracture than exclusive H2RA users (OR: 1.37, 95% CI: 1.26 to 1.50).

Source: Results

Abstract: Conclusions

The risk of osteoporotic fracture increased with the duration of PPI use, especially when PPI was used for ≥1 year and regularly in the recent 1 year.

Source: Conclusions
Authors’ abstract

Background

Patients with peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) are more likely to receive long-term therapy with proton pump inhibitors (PPIs). This study aimed to investigate the risk of osteoporotic fractures in PPI users compared to histamine-2 receptor antagonist (H2RA) users and the association between fractures and the duration and regular use of PPI.

Methods

A population-based, nationwide nested case-control study from January 2006 to December 2015 was performed using Korean National Health Insurance Service claims data. We included patients ≥50 years of age, without previous fractures, newly prescribed with PPI or H2RA, and diagnosed with PUD or GERD from 2006 to 2015. Patients with osteoporotic fracture (n = 59,240) were matched with the non-fracture control group (n = 296,200) at a 1:5 ratio based on sex, age, cohort entry date, follow-up duration, and bisphosphonate use.

The osteoporotic fractures were defined using the diagnostic codes of claims data (M80, M81, M82, M484, M485, S220, S221, S320, S327, S422, S423, S525, S526, S72).

Results

The higher the cumulative use of PPIs, the higher the osteoporotic fracture risk (P for trend < 0.001). The risk of osteoporotic fracture in the patients whose cumulative use of PPI was more than 1 year was higher than that of others (OR: 1.42, 95% CI: 1.32 to 1.52). Patients who regularly used PPI in the recent 1 year had a higher risk of osteoporotic fracture than exclusive H2RA users (OR: 1.37, 95% CI: 1.26 to 1.50).

Conclusions

The risk of osteoporotic fracture increased with the duration of PPI use, especially when PPI was used for ≥1 year and regularly in the recent 1 year.

Publication and source details

Original title: Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease

Joo-Hyun Park; Jessie Lee; Su-Yeon Yu; Jin-Hyung Jung; Kyungdo Han; Do-Hoon Kim; Jinnie Rhee

BMC Geriatrics · 2020

© The Author(s) 2020https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.http://dx.doi.org/10.13039/501100003670National Evidence-based Healthcare Collaborating AgencyNA17-004

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T14:24:14.248301+00:00

DOI: 10.1186/s12877-020-01794-3 · PMC7565339